Results 171 to 180 of about 6,825,486 (291)

Toward Free‐Breathing Renal CEST MRI: Preclinical Evaluation of a Novel Prospective Respiratory Triggering Approach

open access: yesMagnetic Resonance in Medicine, Volume 96, Issue 3, Page 1333-1341, September 2026.
ABSTRACT Purpose Endogenous renal chemical exchange saturation transfer (CEST) imaging enables contrast‐agent‐free assessment of renal metabolism but is highly sensitive to respiratory motion. Existing approaches, such as timed breathing, require high patient compliance or preclinical mechanical ventilation, limiting clinical translation.
Patrik Jan Gallinnis   +12 more
wiley   +1 more source

Public Data Availability and Corporate ESG Performance: Evidence From Online Data‐Sharing Platforms in China

open access: yesInternational Review of Finance, Volume 26, Issue 3, September 2026.
ABSTRACT This study examines whether public data availability improves corporate ESG performance. Exploiting the rollout of China's data‐sharing platforms as a quasi‐natural experiment, we find that platform adoption significantly enhances firms' ESG outcomes. Treated firms exhibit lower toxic emissions, higher labor income shares and charitable giving,
Lixing Deng   +3 more
wiley   +1 more source

Probabilistic quality assurance of biopsy DVH thresholds in HDR prostate brachytherapy under localization uncertainty

open access: yesJournal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Background MR‐US guided biopsies support biologic correlation in HDR prostate brachytherapy, but steep dose gradients and millimeter‐scale localization uncertainty limit the validity of nominal biopsy doses. Purpose To assess how localization uncertainty affects the robustness of biopsy DVH dose thresholds in HDR prostate brachytherapy and to ...
Matthew Muscat   +4 more
wiley   +1 more source

Economic burden of typhoid fever by antimicrobial resistance in India: a modelling study 2023. [PDF]

open access: yesLancet Reg Health Southeast Asia
Mogasale VV   +9 more
europepmc   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 429-439, August 2026.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy